|
It was reported that a shuntassistant (part # fv288t) was implanted during a procedure performed on (b)(6) 2022.According to the complainant, the valve in combination with a progav 2.0 was believed to be operating in overdrainage.The patient underwent a revision procedure.The complaint device was returned to the manufacturer for evaluation.No patient complications were reported as a result of the revision procedure.Age: 17 years, height: 153 centimeters (cm), weight: 57 kilograms (kg), gender: female.Same event as medwatch#3004721439-2022-00435 and 3004721439-2022-00436.
|
|
Visual inspection: in the first step of our investigation, we performed a visual inspection of the product.We have checked for possible damage, deformation of the housing, deposits or other abnormalities.The following observations were made during the visual inspection: deposits.Permeability test: the permeability test was performed at a hydrostatic pressure difference of the pressure setting of the paedisa upon receipt plus 30 cmh2o in the horizontal direction of flow.The test showed that the paedisa is permeable.Computer control test: to check the flow rate of the valve, the valve was tested on a miethke computer controlled testing apparatus and passed the standard test.The flow of the test liquid was reduced step by step from 60 ml/h to 5 ml/h (in accordance with iso 7197).Distilled water was used as the test-liquid.The resulting pressure was measured.The paedisa was tested according to standard procedure in the vertical position.The results indicated that at a reference flow of 20 ml/h in the horizontal position, the paedisa had a pressure of 2.71 cmh2o.This is not within the specified tolerance of 10 cmh2o -2/+4 cmh2o.According to our results, we can detect an accelerated outflow.Internal inspection of product: in order to verify whether the investigated valve was compromised by the known risks of hydrocephalus therapy, e.G.By a build-up of natural substances (protein, blood, or tissue particles) in the cerebrospinal fluid, the valve is finally opened with a special tool.After dismantling of the valve, deposits were found inside.For more detailed visibility, the proteins/deposits in paedisa were coloured by using a colouring solution.[colouring solution consisting of coomassi brilliant blue r mixed with 0.6% ethanol and distilled water].Results: based on our investigation results, we have determined that there was an accelerated outflow in the valve at the time of our investigation.Detected deposits were the cause of the accelerated outflow endogenous substances in the csf can temporarily impair the function of the valve and is described as concomitant symptoms in hydrocephalus therapy.We can exclude a defect at the time of release.The valve system met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.Further actions from our point of view, no further regulatory actions are required.
|